NASDAQ · Biotechnology

Atea Pharmaceuticals, Inc. (AVIR) Stock

$5.12 -0.78% NASDAQ: AVIR Healthcare

Valuation

MetricValue
Price$5.12
Market Cap$409.34M
P/E Ratio-2.47
P/B Ratio2.01
P/S Ratio0.00
EPS (TTM)$-1.94
52-Week High$6.45
52-Week Low$2.84
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-64.25%
ROA-71.16%
ROCE-89.93%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.78

Annual Financials (USD)

Metric20212022202320242025
Revenue$351.0M$0$0$0$0
Operating Profit$138.0M$-131.0M$-164.0M$-193.0M$-181.0M
Net Profit$121.0M$-116.0M$-136.0M$-168.0M$-158.0M
EPS$1.37$-1.39$-1.63$-2.00$-1.94
Op Margin39.4%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$773.0M$667.0M$595.0M$465.0M$315.0M
Total Liabilities$63.0M$26.0M$40.0M$26.0M$40.0M
Cash$764.0M$647.0M$144.0M$65.0M$96.0M
Borrowings$0$3.0M$2.0M$2.0M$1.0M

Latest News

Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment MT Newswires · Jul 14, 2026 Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus GlobeNewswire · Jul 14, 2026 Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America MT Newswires · Jun 25, 2026 Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus GlobeNewswire · Jun 25, 2026 Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know Zacks · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-87.0M$-121.0M$-85.0M$-135.0M$-132.0M
Investing Cash Flow$0$-457.0M$40.0M$56.0M$189.0M
Financing Cash Flow$0$0$0$0$-26.0M
Net Cash Flow$-86.0M$-576.0M$-45.0M$-79.0M$31.0M
Free Cash Flow$-87.0M$-123.0M$-85.0M$-135.0M$-132.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA-1.95
FCF Yield-37.04%
Quick Ratio8.13
Interest Coverage0.00
Return 1Y36.10%
Return 3Y33.80%
Return 5Y-78.78%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUSArbutus Biopharma Corporation $4.25 +1.56% 5.63 $838.57M 0.00%
ALGSAligos Therapeutics, Inc. $5.29 -0.36% -0.76 $32.74M 0.00%
ASMBAssembly Biosciences, Inc. $23.50 +2.98% 40.98 $465.71M 0.00%
COCPCocrystal Pharma, Inc. $1.06 -0.93% -1.49 $14.61M 0.00%
ENTAEnanta Pharmaceuticals, Inc. $12.48 +3.14% -5.32 $362.90M 0.00%

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is led by CEO Jean-Pierre Sommadossi, employs 56 people, headquartered in US, publicly traded since 2020.

Atea Pharmaceuticals, Inc. (AVIR) stock trades at $5.12 with a market capitalization of $409.34M. The stock is valued at a price-to-earnings (P/E) ratio of -2.47, price-to-book of 2.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.84 and $6.45, and currently trades 20.6% below its 52-week high.

On profitability, Atea Pharmaceuticals, Inc. generates a return on equity (ROE) of -64.25%, return on capital employed of -89.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.15 +0.30% JNJ Johnson & Johnson $260.12 +1.42% ABBV AbbVie Inc. $276.42 +1.47% MRK Merck & Company, Inc. Common Stock (new) $146.40 +2.82% UNH UnitedHealth Group Incorporated Common Stock (DE) $382.93 +3.23% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.94 +0.91% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.82 +2.53% ABT Abbott Laboratories $99.46 +0.98% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides